L-Alaninol

L-Alaninol

SCHEMBL2804901

CC(N)CO.CC(N)CO

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ MAPK1 P28482 1/20 0.44
▸ GABRP O00591 2/20 0.38
▸ GABRD O14764 2/20 0.38
▸ GABRA1 P14867 2/20 0.38
▸ GABRB1 P18505 2/20 0.38
▸ GABRG2 P18507 2/20 0.38
▸ GABRB3 P28472 2/20 0.38
▸ GABRA5 P31644 2/20 0.38
▸ GABRA3 P34903 2/20 0.38
▸ GABRA2 P47869 2/20 0.38
▸ GABRB2 P47870 2/20 0.38
▸ GABRA4 P48169 2/20 0.38
▸ GABRE P78334 2/20 0.38
▸ GABRA6 Q16445 2/20 0.38
▸ GABRG1 Q8N1C3 2/20 0.38
▸ GABRG3 Q99928 2/20 0.38
▸ GABRQ Q9UN88 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Alaninol SCHEMBL72189 1.00 — —
L-Alaninol SCHEMBL30417235 1.00 — —
L-Alaninol SCHEMBL82137 1.00 — —
L-Alaninol SCHEMBL30499 1.00 — —
L-Alaninol SCHEMBL1331749 1.00 — —
L-Alaninol SCHEMBL7787362 1.00 TSHR (0.54) TSHRALDH1A1TDP1MAPK1GABRP
L-Alaninol SCHEMBL1055334 0.96 — —
L-Alaninol SCHEMBL16212089 0.96 — —
L-Alaninol SCHEMBL22710985 0.96 — —
L-Alaninol SCHEMBL8093475 0.96 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202999-A9 METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2023-06-29 — — US disclosed
US-20100240894-A1 METHOD FOR PRODUCING AMINES FROM GLYCERIN BASF SE (DE) 2010-09-23 — — US disclosed
EP-2185499-A1 METHOD FOR PRODUCING AMINES FROM GLYCERIN BASF SE (DE) 2010-05-19 — — EP disclosed
WO-2009027248-A1 METHOD FOR PRODUCING AMINES FROM GLYCERIN BASF SE (DE) 2009-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202999-A9 METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS PIR, PUM1, ZRANB2 TSHR 3264/4885ALDH1A1 873/4885TDP1 2987/4885
US-20100240894-A1 METHOD FOR PRODUCING AMINES FROM GLYCERIN GNMT, GK, GMPS TSHR 4722/4885ALDH1A1 1327/4885TDP1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback